IL154984A0 - Estrogen receptor modulators - Google Patents

Estrogen receptor modulators

Info

Publication number
IL154984A0
IL154984A0 IL15498401A IL15498401A IL154984A0 IL 154984 A0 IL154984 A0 IL 154984A0 IL 15498401 A IL15498401 A IL 15498401A IL 15498401 A IL15498401 A IL 15498401A IL 154984 A0 IL154984 A0 IL 154984A0
Authority
IL
Israel
Prior art keywords
estrogen receptor
receptor modulators
modulators
estrogen
receptor
Prior art date
Application number
IL15498401A
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of IL154984A0 publication Critical patent/IL154984A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D411/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32Antioestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D327/00Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06Six-membered rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D339/00Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/08Six-membered rings
IL15498401A 2000-10-19 2001-10-15 Estrogen receptor modulators IL154984A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24158200P 2000-10-19 2000-10-19
PCT/US2001/042735 WO2002032377A2 (en) 2000-10-19 2001-10-15 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
IL154984A0 true IL154984A0 (en) 2003-10-31

Family

ID=22911282

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15498401A IL154984A0 (en) 2000-10-19 2001-10-15 Estrogen receptor modulators

Country Status (20)

Country Link
EP (1) EP1333827A2 (en)
JP (1) JP2004511502A (en)
KR (1) KR20030042020A (en)
CN (1) CN1469743A (en)
AU (2) AU2002232381B2 (en)
BG (1) BG107676A (en)
BR (1) BR0114689A (en)
CA (1) CA2424729A1 (en)
EA (1) EA200300474A1 (en)
EC (1) ECSP034558A (en)
EE (1) EE200300153A (en)
HU (1) HUP0303563A2 (en)
IL (1) IL154984A0 (en)
IS (1) IS6761A (en)
MX (1) MXPA03003485A (en)
NO (1) NO20031737L (en)
PE (1) PE20021083A1 (en)
PL (1) PL361053A1 (en)
SK (1) SK4772003A3 (en)
WO (1) WO2002032377A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030225132A1 (en) * 2002-04-11 2003-12-04 Dininno Frank P. Estrogen receptor modulators
ES2350446T3 (en) * 2002-04-24 2011-01-24 MERCK SHARP & DOHME CORP. MODULATORS OF ESTROGEN RECEIVERS.
CA2512000C (en) * 2002-12-26 2011-08-09 Eisai Co., Ltd. Selective estrogen receptor modulator
AU2006275514B2 (en) * 2005-07-29 2012-04-05 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
AU2006307046A1 (en) 2005-10-27 2007-05-03 Msd K.K. Novel benzoxathiin derivative
CN101641339B (en) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 Compounds for the prevention and treatment of cardiovascular diseases
AU2010204106B2 (en) 2009-01-08 2014-05-08 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
MX2021012876A (en) 2009-03-18 2022-06-23 Resverlogix Corp Novel anti-inflammatory agents.
ES2821018T3 (en) 2009-04-22 2021-04-23 Resverlogix Corp New anti-inflammatory agents
CN102939287B (en) 2010-06-10 2016-01-27 塞拉根制药公司 Estrogenic agents and uses thereof
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
PT2773354T (en) 2011-11-01 2019-07-17 Resverlogix Corp Oral immediate release formulations for substituted quinazolinones
US9193714B2 (en) 2011-12-14 2015-11-24 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Also Published As

Publication number Publication date
MXPA03003485A (en) 2003-07-14
PE20021083A1 (en) 2002-12-16
WO2002032377A2 (en) 2002-04-25
WO2002032377A3 (en) 2002-08-22
BR0114689A (en) 2003-07-01
PL361053A1 (en) 2004-09-20
JP2004511502A (en) 2004-04-15
SK4772003A3 (en) 2003-08-05
NO20031737D0 (en) 2003-04-15
EE200300153A (en) 2003-06-16
ECSP034558A (en) 2003-06-25
NO20031737L (en) 2003-06-19
EA200300474A1 (en) 2003-10-30
KR20030042020A (en) 2003-05-27
AU2002232381B2 (en) 2004-11-18
BG107676A (en) 2003-11-28
AU3238102A (en) 2002-04-29
HUP0303563A2 (en) 2004-03-01
EP1333827A2 (en) 2003-08-13
CA2424729A1 (en) 2002-04-25
CN1469743A (en) 2004-01-21
IS6761A (en) 2003-03-27

Similar Documents

Publication Publication Date Title
PL374215A1 (en) Selective estrogen receptor modulators
EG25606A (en) Glucocorticoid receptor modulators
IL150912A0 (en) Adenosine receptor modulators
EP1200581A4 (en) Truncated egf receptor
EP1418900A4 (en) Selective estrogen receptor modulators
AU3238102A (en) Estrogen receptor modulators
HK1068875A1 (en) Tetracyclic heterocompounds as estrogen receptor modulators
IL146151A0 (en) Human-g-protein receptor
GB0000474D0 (en) Receptor
AU1252102A (en) Receptor
AUPQ563400A0 (en) Novel receptor
GB9913649D0 (en) Estrogen receptor
SG100688A1 (en) Enzymatic resolution of selective estrogen receptor modulators
GB0100301D0 (en) Estrogen receptor
GB0100299D0 (en) Estrogen receptor
GB0100298D0 (en) Estrogen receptor
AU2002252533A1 (en) Estrogen receptor modulators
SI1467998T1 (en) Tetracyclic heterocompounds as estrogen receptor modulators
GB0016230D0 (en) Estrogen receptors
GB0031096D0 (en) Receptor
GB0009269D0 (en) Receptor
GB0014761D0 (en) Receptor
GB9806032D0 (en) Estrogen receptor
AU2002249971A1 (en) Piperazinyltriazines as estrogen receptor modulators
AUPQ915300A0 (en) Receptor